TECTONIC THERAPEUTIC, INC. Deferred Income Tax Expense (Benefit)
TECTONIC THERAPEUTIC, INC. (TECX) reported Deferred Income Tax Expense (Benefit) of $18.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- TECTONIC THERAPEUTIC, INC. deferred income tax expense (benefit) for fiscal 2025 was $18.68M, a 10.35% increase from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. deferred income tax expense (benefit) for fiscal 2024 was $16.93M, a 16.19% increase from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. deferred income tax expense (benefit) for fiscal 2023 was $14.57M.
- TECTONIC THERAPEUTIC, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $18.68M 10-K · filed 2026-02-26 |
| 2024-12-31 | $16.93M 10-K · filed 2026-02-26 |
| 2023-12-31 | $14.57M 10-K · filed 2025-03-20 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-17 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-18 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-16 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |